Download UCLH Cancer Collaborative and the

UCLH Cancer Collaborative and the
Centre for Cancer Outcomes
Projects aiming to improve End of Life Care
Kate Farrow
Programme manager for London Cancer & New Care Models
UCLH Cancer Collaborative
On behalf of :Prof Kathy Pritchard-Jones (CMO, UCLH Cancer Collaborative)
Prof Mick Peake (Director) & Dr Emma Kipps, clinical fellow, Centre for Cancer Outcomes
Along the patient journey
Evidence & research. Collaboration. Implementation
1. Characterisation of patient pathway when approaching EOL:
• Analysis of the key cancer procedures and unplanned admissions to hospital in the last 90
days of life (Dr Emma Kipps, clinical fellow; Prof Mick Peake in collaboration with PHE)
2. Joined up services and systems
• Collaboration with STP EOLC and digital workstreams to increase use of technology to
personalise urgent care plans
3. Improving primary and secondary care input into Personalised Care planning throughout
the
: pathway
• Provision of ‘Recovery Package’ (Lead: Sharon Cavanagh)
Holistic Needs Assessments, End of Treatment Summary, Health and Wellbeing Events,
Cancer Care Review to support individuals to live as actively and well as possible and to be
responsive to changing individual/clinical needs
National Guidance
•Independent Cancer Taskforce
•
People nearing the end of their life should be supported to make decisions regarding
their own care to live well until they die
•
Early planning should be in place
•
NHS England should ensure that CCGs commission appropriate integrated services for
palliative and end of life care.
•The UCLH Cancer Collaborative, part of the national cancer vanguard
•
To improve the standards of cancer care, patient experience, quality of life and clinical
outcomes for cancer patients.
•
To improve commissioning, accountability and provision.
3
Place of death
• The NHS Forward View Planning guidance11
• STPs should include improving patient experience related to end
of life care
• Ensuring an increase in the number of people enabled to die in
their place of choice, including at home.
• Despite 73% of patients reporting their wish to die at home, 53%
still die in an NHS hospital.
• In London
• Large variability between the CCGs
11 Delivering the Forward View: NHS planning guidance. 2016/17 – 2020/21. (December 2015).
Proportion of patients who died in 2015, whose death was in their usual place of residence by
London and Greater Manchester CCGs. All age groups combined.
Steve Scott, RM Partners, November 2016
Proportion of patients who died in a hospital, a care home, a hospice or their own home in 2015.
In all age bands, NCEL and W
Essex has a higher rate of
death in hospital than the
England average.
Steve Scott, RM Partners, November 2016
Early identification and better characterisation of patient
pathway when approaching EOL:
• ‘Vanguard’ project that aims to analyse the morbidity
associated with use of > first line chemotherapy and
consequent time spent in hospital in the 90 days before death
• To have a greater understanding of the morbidity associated with
active treatment and use of health care provisions towards end of life
• To encourage physician-patient discussions regarding likely prognosis
• To empower health care professionals and therefore patients with the
morbidity associated with treatment to facilitate informed decisions
Planned second phase of analytical project:
• Future analyses to include the use of radiotherapy, major and non-major
surgical interventions and time spent in a hospital bed in the 90 days before
death
• Aim is to inform earlier recognition of when patients are entering EOLC
• Analyses could be used to:
• Improve quality of life through better informed joint decision making
regarding treatment options and likely impact and prognosis
• Improve patient experience and use resources more appropriately
• For example: Use of ambulatory care to reduce hospitalisation for palliative
drains or stents
Palliative chemotherapy
• The morbidity associated with treatment is poorly described.
• ASCO recommended against the use of chemotherapy in solid tumor patients
who have not benefited from prior treatment and who have a performance
status of 3 or 4 4,5.
• Hence, it is patients with good performance status who are most likely to receive
chemotherapy near the end of life.
4. Pater, J. L. & Loeb, M. Nonanatomic prognostic factors in carcinoma of the lung: a multivariate analysis. Cancer 50, 326-331
(1982).
5. Stanley, K. E. Prognostic factors for survival in patients with inoperable lung cancer. Journal of the National Cancer Institute 65,
25-32 (1980).
From: Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
JAMA Oncol. 2015;1(6):778-784. doi:10.1001/jamaoncol.2015.2378
However, patients with good
performance status, who receive
additional palliative
chemotherapy, have a
significantly worse QOL at the
end of life than those who do not
receive chemotherapy
Figure Legend:
Patients’ Higher Quality of Life Near Death Stratified by Baseline Performance Status and Chemotherapy UseECOG indicates Eastern Cooperative Oncology
Group. Performance status was measured by ECOG score as follows: 1, symptomatic, ambulatory; 2, symptomatic, in bed less than 50% of the time; and 3,
symptomatic, in bed more than 50% of the time. Criteria used to evaluate higher quality of life near death are detailed in the Methods section.
Copyright © 2017 American Medical
Association. All rights reserved.
Palliative chemotherapy
Patients with chemotherapy refractory cancer, who receive further
chemotherapy within the last 4 months of life
• More likely to receive cardiopulmonary resuscitation
• Less likely to die at home 7
Morbidity is significant
• 56% of patients reported significant toxicity (Grade 3 or 4)
following the last cycle of chemotherapy (NCEPOD, 2008)
7 Wright, et al ,. Bmj 348, g1219, doi:10.1136/bmj.g1219 (2014) (US data)
Palliative chemotherapy
• Clinicians have a responsibility to outline the role of chemotherapy in the context of
2nd or 3rd line treatment for metastatic disease.
• In order for patients to make an informed decision, oncologists must both
acknowledge the terminal nature of a patient’s illness 8,9 and be explicit about the
chance of benefit from treatment.
• A greater understanding of the morbidity associated with treatment will help to
facilitate this discussion.
8 Prigerson, H. G. et al. Journal of clinical oncology : 33, 30, (2015) (US data)
9 Epstein, A. S.,. Journal of clinical oncology 34, 2398-2403, (2016) (US data)
Cancer patient Bed Use
London and West Essex, 2010-2014, analysis by Katherine Henson, PHE with TCST
http://www.ncin.org.uk/local_cancer_intelligence/tcst
Emergency admissions accounted for:
• 12% of all cancer patient admissions but 61% of the total length of stay.
Length of stay varied between tumour type
• Breast and colorectal cancer, 52% of hospital admissions were unplanned
• Lung and prostate cancer, 70% of hospital admissions unplanned
Medical oncology had most admissions and longest length of stay
• Avoiding unnecessary or emergency hospitalisations is
often in line with patient preference and has the
potential for significant cost savings
• Underlying contributing factors
• Maybe in part due to fragmentation of health and social care
• However, chemotherapy within the last 3 months of life may also
contribute
• Imperative to better understand the morbidity
associated with treatment for incurable disease
Summary of UCLH Cancer Vanguard project
in collaboration with PHE
• Project outline: A London-wide descriptive analysis correlating the use of
chemotherapy and unplanned hospital admissions in the last 90 days of life of
patients diagnosed with breast, lung, colorectal, prostate and pancreatic
cancer in 2015, linked to performance status and place of death.
• Project output: Improved understanding of the morbidity associated with
active treatment towards the end of life and impact on use of health care
provision and place of death.
• Locally generated contemporary data to inform conversations between
oncologists and patients with only palliative treatment options, to improve
joint decision making and care planning
Along the patient journey
Evidence & research. Collaboration. Implementation
1. Characterisation of patient pathway when approaching EOL:
• Analysis of the key cancer procedures and unplanned admissions to hospital in the last 90
days of life (Dr Emma Kipps, clinical fellow; Prof Mick Peake in collaboration with PHE)
2. Joined up services and systems
• Collaboration with STP EOLC and digital workstreams to increase use of technology to
personalise urgent care plans
3. Improving primary and secondary care input into Personalised Care planning throughout
the
: pathway
• Provision of ‘Recovery Package’ (Lead: Sharon Cavanagh)
Holistic Needs Assessments, End of Treatment Summary, Health and Wellbeing Events,
Cancer Care Review to support individuals to live as actively and well as possible and to be
responsive to changing individual/clinical needs